Slide 1: Corporate Presentation
Corporate Presentation August 2026 Nasdaq: MNKD © Copyright 2026. All rights reserved. Mannkind Corporation.
Slide 2: Cautionary Statement
Cautionary Statement Statements in this presentation that are not statements of historical fact are forward-looking statements that involve risks and uncertainties. Words such as “believes”, “anticipates”, “plans”, “expects”, “intend”, “will”, “goal”, “potential” and similar expressions are intended
Slide 3: Transforming Chronic Disease Care Through Innovative Patient-Centric Solutions
Transforming Chronic Disease Care Through Innovative Patient- Centric Solutions for Cardiometabolic and Orphan Lung Diseases 3 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 4: Major Catalysts Driving 2026 & Beyond
Major Catalysts Driving 2026 & Beyond Afrezza® Pediatrics Furoscix ReadyFlow Nintedanib DPI • Indication expansion • Reduces administration from • Urgent need for new, effective hours to seconds via an therapies in IPF • Unique value proposition autoinjector addressing patient unmet • Lung targeted
Slide 5: Q2 2026: Beyond the Catalysts
Q2 2026: Beyond the Catalysts • Afrezza pediatric launch off to a strong start — top 20 key target institutions have all written a prescription – Breakthrough T1D grant awarded to advance the INHALE-1ST trial • Furoscix®: strong revenue growth (+43%) over Q1 • Enrollment underway in the nintedanib D
Slide 6: Q2 2026 Performance Summary
Q2 2026 Performance Summary Source Revenue % Change vs Q1 2026 $111M Furoscix $22.2 M 43% Cash, cash equivalents and investments as of June 30, 2026 Afrezza $17.0 M 9.7% $50M PIPE* V-Go1 $2.8 M 12.9% Proceeds will fund the $45 million CVR payment triggered by the FDA approval of Furoscix ReadyFlow R
Slide 7: Afrezza
7 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 8: Pediatric T1D Entry Point Creates Meaningful Revenue Potential and Long-Term Adult Growth
Pediatric T1D Entry Point Creates Meaningful Revenue Potential and Long-Term Adult Growth Type 2 DM AFREZZA PEDIATRIC FOCUS >36M U.S. ~$150M potential annual pediatric T1D revenue opportunity for every 10% share captured¹ Type 1 DM >2M U.S. ~360K Age 6-22 living with T1D Type 1 DM Pediatrics ~30K >3
Slide 9: Afrezza Now Approved for Pediatric Patients Living with Diabetes 6 Years and Older
Afrezza Now Approved for Pediatric Patients Living with Diabetes 6 Years and Older The first alternative to mealtime injections in 100+ years of pediatric treatments Differentiated clinical profile • Ultra-rapid onset and earlier peak — insulin action closer to how children actually eat and live day
Slide 10: Why Afrezza in Pediatrics Is Different
Why Afrezza in Pediatrics Is Different A concentrated, targetable market A connected, patient-centric community ADULT PEDIATRICS ADULT PEDIATRICS >60,000 prescribers = <1,000 prescribers = Prescriber-only target, Prescribers + caregivers, 80% of RAA market 80% of pediatric Rx limited surround sound
Slide 11: Afrezza Now Recognized in ADA Standards of Care
Afrezza Now Recognized in ADA Standards of Care •Inhaled insulin is recognized as a therapeutic option along with MDI and AID • ADA Standards (Section 9: Pharmacologic Treatment; Figure 9.2) now recommend clinicians evaluate inhaled insulin as a prandial option at every patient visit—moving it into
Slide 12: Innovation Roadmap in Afrezza
Innovation Roadmap in Afrezza Product Development, Digital Advancements and Global Expansion Roadmap Updated FDA Afrezza 2-unit cartridge Anticipated approval approved dose conversion High Concentration Afrezza Potential for up to a 20-unit cartridge, ADA guideline INHALE IQ enabling entry into the
Slide 13: Furoscix
13 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 14: Furoscix ReadyFlow Now Approved
Furoscix ReadyFlow Now Approved The first and only IV-equivalent diuretic delivered via autoinjector Designed for at-home intervention • Treats fluid overload in adults with HF or CKD outside the hospital setting • May support earlier intervention beyond the hospital – across outpatient, post-discha
Slide 15: Furoscix Can Address Fluid Overload Across the Patient Journey
Furoscix Can Address Fluid Overload Across the Patient Journey STABLE PATIENT TREATED AT HOME WITH ORAL DIURETIC POST-HOSPITAL DISCHARGE Use Furoscix to: EARLY INTERVENTION • Discharge early and ~1M When fluid overload first resolve residual Addressable presents, use Furoscix: Fluid Overload congest
Slide 16: HF and CKD Place a Significant Economic Burden on the U.S. Healthcare System
HF and CKD Place a Significant Economic Burden on the U.S. Healthcare System Heart Failure Chronic Kidney Disease Direct medical costs from heart ~15% of Medicare FFS beneficiaries have failure in the U.S. is projected to diagnosed CKD, yet they account for ~27% approach $70B by 20301 of total spend
Slide 17: Growth Opportunities
Since Q1, MannKind Advanced Key Furosicx Growth Opportunities Identified Challenges Opportunities 1 Limited Hospital Presence Increase IDN engagement to drive stronger hospital pull-through +36% QoQ IDN Growth (Q2 2026 vs. Q1 2026 ) 2 Diluted Salesforce Focus Sharpen cardiology and nephrology specia
Slide 18: Furoscix ReadyFlow Approval Enables a Pathway for IDN Growth
Furoscix ReadyFlow Approval Enables a Pathway for IDN Growth 01 Establish 02 Embed 03 Expand Engage priority IDNs Integrate into care Scale across the pathways health system Build awareness and Support discharge, post- Reach more patients, clinical confidence discharge and outpatient providers and c
Slide 19: Furoscix ReadyFlow Launch Campaign is Built to Drive Immediate Awareness and Adoption
Furoscix ReadyFlow Launch Campaign is Built to Drive Immediate Awareness and Adoption Field activation begins immediately • Sales force launch training and deployment underway • Integrated HCP and patient campaign ready across digital, field and point-of-care channels • Major cardiology and nephrolo
Slide 20: Nintedanib DPI
Nintedanib DPI 20 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 21: A Validated Category + Persistent Unmet Need Creates an Opportunity for Targeted Inhaled Approaches
A Validated Category + Persistent Unmet Need Creates an Opportunity for Targeted Inhaled Approaches U.S. MARKET LANDSCAPE ~650,000 patients with ILDs >$150K annual brand pricing / patient >200 ILD subtypes can progress to fibrosis >$40B ~100,000+ ~180,000 implied U.S. total addressable market patien
Slide 22: IPF: A Progressive and Fatal Disease with Problematic Therapies
IPF: A Progressive and Fatal Disease with Problematic Therapies 3 • Current therapies exhibit major safety and tolerability issues • Discontinuation rates out of 4 are as high as 50%1 patients with IPF are not on an approved • A minority of patients even start IPF therapy antifibrotic therapy1 • 80%
Slide 23: Local Delivery, Systemic Advantage: A Potentially Better Path Forward
Local Delivery, Systemic Advantage: A Potentially Better Path Forward Target the lungs directly Bypass the GI tract Improve efficacy and tolerability Efficient, targeted Lower systemic exposure May support long-term deep-lung delivery adherence 23 © Copyright 2025. All rights reserved. MannKind Corp
Slide 24: INFLO-1 Phase 1b: First-in-Patient Study to Assess Safety, Tolerability and Pharmacokinetics
INFLO-1 Phase 1b: First-in-Patient Study to Assess Safety, Tolerability and Pharmacokinetics Multiple-Ascending Dose (7 Days) (n = 27; 2:1 randomization) Safety Data Review COHORT 1 (Sponsor & External DSMB) COHORT 2 2 mg TID 4 mg BID Objectives Early Safety Data Pulmonary Tolerability Multiple-Asce
Slide 25: Phase 1b: A Clean Safety Profile in First IPF Study
Phase 1b: A Clean Safety Profile in First IPF Study 0 0 0 Safety Signals Bronchospasms Discontinuations None of the diarrhea, A known risk for inhaled Where current oral therapies nausea or vomiting that limits powders — none observed, see discontinuation rates as oral nintedanib (OFEV®) even in fib
Slide 26: Phase 1b Cough: Mild and Transient
Phase 1b Cough: Mild and Transient Most patients had no cough — and when it occurred, it was mild and led to zero discontinuations. Cough was not correlated to powder mass. ~60% of patients had NO cough ~30% of patients had a mild cough 0 discontinuations from cough (11 of 18 on active drug) No seve
Slide 27: INFLO-2 Phase 2: Global Enrollment Underway in IPF
. INFLO-2 Phase 2: Global Enrollment Underway in IPF STUDY DESIGN Phase 2 Controlled Study Phase 2 Open-Label Extension • Randomization 2:2:1:1 (12 weeks) (24 weeks) • Sample size 210 • Aged 40-85 Nintedanib DPI 4 mg BID Nintedanib DPI 4 mg BID • Patients with IPF without current background IPF Nint
Slide 28: MannKind Has Three Shots on Goal in IPF
MannKind Has Three Shots on Goal in IPF One proven platform. One large, under-served market. Nintedanib DPI Proven molecule, now with proven 1 Wholly-owned tolerability in IPF. Phase 2 underway. 2 Tyvaso DPI United Therapeutics Partnership Currently approved in PAH and PH-ILD. Future expansion into
Slide 29: United Therapeutics Collaboration
United Therapeutics Collaboration 29 © Copyright 2026. All rights reserved. MannKind Corporation.
Slide 30: United Therapeutics Collaboration Expansion
United Therapeutics Collaboration Expansion • Tyvaso DPI >250K Patients – Durable economics in the combined disease states – potential expansion into IPF – MannKind is the sole Progressive Pulmonary Fibrosis (PPF) manufacturer • Ralinepag DPI (MNKD-1501) Idiopathic Pulmonary Fibrosis (IPF) – $5M rec
Slide 31: Momentum Ahead
Momentum Ahead
Slide 32: Well-Positioned for Next Phase of Growth
Well-Positioned for Next Phase of Growth Strategic Revenue Diversification Diversification strategy execution continues, commercial products now ~54% of 1H26 revenue as the mix shifts decisively toward MannKind brands FUROSCIX ReadyFlow Now Approved FDA-approved July 2026, unlocking a new delivery p
Slide 33: MNKD Products & Pipeline
MNKD Products & Pipeline Cardiometabolic Orphan Lung Product Targeted Indications Pre-IND Phase 1 Phase 2 Phase 3 Approval Afrezza® (insulin human) T1DM / T2DM Marketed Inhalation Powder (aged 6 and older) V-Go® All-in-One T1DM / T2DM Marketed Insulin Delivery Patch (adults) Furoscix® / Furoscix Rea
Slide 34: © Copyright 2025. All rights reserved. MannKind Corporation.
34 © Copyright 2025. All rights reserved. MannKind Corporation.